Avtor/Urednik | Gužič-Salobir, Barbara; Keber, Irena; Vrabič, Lucija | |
Naslov | A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women | |
Tip | članek | |
Vir | Fertil Steril | |
Vol. in št. | Letnik 78, št. 6 | |
Leto izdaje | 2002 | |
Obseg | str. 1178-83 | |
Jezik | eng | |
Abstrakt | Objective: To investigate the effects of combined hormone replacement therapy (HRT) on various parameters of coagulation and fibrinolysis that may contribute to increased risk for venous thromboembolic events. Design: Prospective, randomized, double-blind, placebo-controlled study. Setting: Academic hospital. Patient(s): Sixty-one healthy postmenopausal women with intact uterus. Intervention(s): Patients were randomized to receive continuous combined HRT (estradiol, 2 mg/d, and norethisterone acetate, 1 mg/d) or placebo for 6 months. Main Outcome Measure(s): Markers of coagulation and fibrinolysis were measured before therapy and after 3 and 6 months of therapy. Result(s): The groups did not differ significantly in levels of prothrombin fragments 1 and 2 and thrombinantithrombin III complex after 3 and 6 months of therapy. After 6 months of HRT, significant decreases in activity of antithrombin III and protein C and levels of plasminogen activator inhibitor-1 antigen, tissue-type plasminogen activator antigen, and euglobulin clot lysis time and a significant increase in n-dimer level were found compared with placebo. Conclusion(s): Continuous combined HRT for several months produced no net activation of coagulation but improved fibrinolysis in healthy postmenopausal women with no risk factors for venous thromboembolic events. | |
Deskriptorji | POSTMENOPAUSE ESTROGEN REPLACEMENT THERAPY THROMBOPHLEBITIS MIDDLE AGE BLOOD COAGULATION TESTS ESTRADIOL NORETHINDRONE ANTITHROMBIN III PROTEIN C PLASMINOGEN ACTIVATOR INHIBITOR 1 RANDOMIZED CONTROLLED TRIALS |